United Therapeutics Corp. (Nasdaq: UTHR) announced its pivotal TETON-1 study for Tyvaso in idiopathic pulmonary fibrosis met its primary and a key secondary endpoint, with results published in the New England Journal of Medicine.
"The profound impact of the TETON clinical program... represents a truly important advancement for people living with this progressive, life-threatening disease,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.
The Phase 3 study showed that nebulized Tyvaso slowed the decline of lung function, measured by forced vital capacity (FVC), by 130.1 mL at 52 weeks compared to placebo (p<0.001). A combined analysis of the TETON-1 and TETON-2 studies also showed a 33% reduction in the risk of clinical worsening (p=0.0034).
United Therapeutics plans to seek priority FDA review for the expanded indication by the end of summer 2026. Success would open up the drug to an estimated 100,000-plus IPF patients in the U.S., a significant market expansion beyond its current approved uses in pulmonary hypertension.
The TETON-1 study, which enrolled 598 patients in the U.S. and Canada, demonstrated that patients taking nebulized Tyvaso had a median FVC decline of just 43.3 mL over 52 weeks, compared to a 196.2 mL decline in the placebo group. The results were consistent across all patient subgroups, regardless of background therapy.
A combined analysis of the TETON-1 and the international TETON-2 study was also presented, reinforcing the findings. In this larger dataset, Tyvaso showed a statistically significant 31% reduction in the risk of clinical worsening and a 48% reduction in the risk of acute IPF exacerbations compared to placebo.
“The combined analysis provides an incredibly powerful dataset with both studies complementing each other well," said Steven D. Nathan, M.D., Chair of the TETON Steering Committee. "These findings have the potential to fundamentally impact how we target IPF and manage patients living with this devastating disease.”
The company confirmed it will submit a supplemental New Drug Application to the U.S. Food and Drug Administration based on the data from both TETON studies. The FDA has already granted orphan designation for treprostinil, the active ingredient in Tyvaso, for the treatment of IPF.
The positive data strengthens United Therapeutics' growth narrative, which hinges on expanding Tyvaso's label. Investors will now watch for the FDA's response to the supplemental New Drug Application, expected to be submitted by the end of summer.
This article is for informational purposes only and does not constitute investment advice.
